ANB-101

N/A

Report date: 2025/05/14 14:10:39

Base Information

Drug NameANB-101
Drug Alias NameCBS-004ANB101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-C-Type lectin domain family 4 member C
TargetsC-Type lectin domain family 4 member C
Therapy Area/IndicationsInflammationScleroderma, SystemicLupus Erythematosus, Systemic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCapella Bioscience Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnaptysbio Inc
Inactive CompaniesN/A
Active IndicationsInflammationScleroderma, SystemicLupus Erythematosus, Systemic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A